Serial re-challenge with influenza vaccine as a tool to study individual immune responses.
With new treatments of inflammatory diseases targeting key inflammatory pathways follows an increased risk for infections. The aim of the present study was to identify an immunological readout where consecutive immunizations induce reproducible immune responses. Such a method could be used as a tool to assess drug-induced immunomodulation in individual patients by comparing responses to the immunizations before and after introduction of a specific treatment. Importantly, the vaccine is merely used as a model antigen and protective immunity is not the primary aim of the method. Eleven volunteers were immunized with influenza vaccine three times, four weeks apart. In order to find the optimal readout for the method, immune responses to the immunizations were measured as circulating antigen-specific B-cells, serum antibody titers and avidity, T-cell proliferation and cytokine secretion. The first exposure to the influenza vaccine induced a stronger B- and T-cell responses than the consecutive immunizations. The second and third immunizations induced comparable but lower B-cell responses as measured by ELISPOT. In summary, we have measured immune responsiveness by using repeated immunizations with influenza virus vaccine as the model antigen. The induction of comparable B-cell responses after the second and third serial immunizations provides a possibility to investigate effects on immune responsiveness by immunomodulatory drugs. The method also allows humoral memory and immune competence per se to be studied on a cellular level in different patient groups.
Vallerskog
Therese
T
Rheumatology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. therese.wallerskog@ki.se
Gaines
Hans
H
Feldman
Adina
A
Culbert
Eric
E
Klareskog
Lars
L
Malmström
Vivianne
V
Trollmo
Christina
C
D000328:Adult; D000914:Antibodies, Viral / Q000276:immunology*; D000917:Antibody Formation / Q000187:drug effects*; D000956:Antigens, Viral / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology*; D016207:Cytokines / Q000276:immunology; D005260:Female; D006801:Humans; D007114:Immunization; D007124:Immunoenzyme Techniques / Q000379:methods; D007155:Immunologic Factors / Q000008:administration & dosage / Q000276:immunology* / Q000494:pharmacology; D007156:Immunologic Memory / Q000187:drug effects*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D008297:Male; D018448:Models, Immunological; D013601:T-Lymphocytes / Q000276:immunology*
D000914:Antibodies, Viral; D000956:Antigens, Viral; D016207:Cytokines; D007155:Immunologic Factors; D007252:Influenza Vaccines